{
    "clinical_study": {
        "@rank": "137989", 
        "acronym": "PAC326", 
        "arm_group": [
            {
                "arm_group_label": "Pacritinib, Once Daily", 
                "arm_group_type": "Experimental", 
                "description": "Pacritinib 400 mg taken orally, once daily"
            }, 
            {
                "arm_group_label": "Pacritinib, Twice Daily", 
                "arm_group_type": "Experimental", 
                "description": "Pacritinib 200 mg taken orally, twice daily"
            }, 
            {
                "arm_group_label": "Best Available Therapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Best Available Therapy includes any physician-selected treatment for primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis, such as approved JAK2 inhibitors, and may include any treatment received before study entry. Best Available Therapy may include ruxolitinib, other approved JAK2 inhibitors, hydroxyurea, glucocorticoids, erythropoietic agents, immunomodulatory agents, mercaptopurine, danazol, interferons, cytarabine, melphalan, or other agents and may also include no treatment and symptom-directed treatment without myelofibrosis-specific treatment."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary hypothesis of the study is that treatment with either once-daily or twice-daily\n      pacritinib results in a greater proportion of patients with thrombocytopenia and\n      myelofibrosis achieving \u2265 35% reduction in spleen volume from baseline to Week 24 than\n      treatment with Best Available Therapy, and a greater proportion of patients achieving a \u2265\n      50% reduction in total symptom score from baseline to Week 24 as measured by the\n      Myeloproliferative Neoplasm Symptom Assessment Form 2.0."
        }, 
        "brief_title": "Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia", 
        "completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Primary Myelofibrosis", 
            "Post-polycythemia Vera Myelofibrosis", 
            "Post-essential Thrombocythemia Myelofibrosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Primary Myelofibrosis", 
                "Polycythemia", 
                "Polycythemia Vera", 
                "Thrombocythemia, Essential", 
                "Thrombocytopenia", 
                "Thrombocytosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Intermediate -1 or -2 or high-risk Myelofibrosis (per Passamonti et al 2010)\n\n          -  Thrombocytopenia (platelet count \u2264 100,000/\u00b5L) at any time after signing informed\n             consent\n\n          -  Palpable splenomegaly \u2265 5 cm on physical examination\n\n          -  Total Symptom Score \u2265 13 on the MPN-SAF TSS 2.0, not including the inactivity\n             question\n\n          -  Patients who are platelet or red blood cell transfusion-dependent are eligible\n\n          -  Adequate white blood cell counts (with low blast counts), liver function, and renal\n             function\n\n          -  At least 6 months from prior splenic irradiation\n\n          -  At least 1-4 weeks since prior myelofibrosis therapy, including any erythropoietic or\n             thrombopoietic agent\n\n          -  Not pregnant, not lactating, and agree to use effective birth control\n\n          -  Able and willing to undergo frequent MRI or CT assessments and complete symptom\n             assessments using a patient-reported outcome instrument\n\n        Exclusion Criteria:\n\n          -  Prior treatment with more than 2 JAK2 inhibitors or with pacritinib\n\n          -  More than 6 months of cumulative prior JAK2 inhibitor treatment\n\n          -  History of (or plans to undergo) spleen removal surgery or allogeneic stem cell\n             transplant\n\n          -  Ongoing gastrointestinal medical condition such as Crohn's disease, Inflammatory\n             bowel disease, chronic diarrhea, or constipation\n\n          -  Active bleeding that requires hospitalization during the screening period\n\n          -  Cardiovascular disease, including recent history or currently clinically symptomatic\n             and uncontrolled: congestive heart failure, arrhythmia, angina, QTc prolongation or\n             other QTc risk factors, myocardial infarction\n\n          -  Other malignancy within last 3 years other than certain limited skin, cervical,\n             prostate, breast, or bladder cancers\n\n          -  Other ongoing, uncontrolled illnesses (including HIV infection and active hepatitis\n             A, B, or C), psychiatric disorder, or social situation that would prevent good care\n             on this study\n\n          -  Life expectancy < 6 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02055781", 
            "org_study_id": "PERSIST-2 (PAC326)"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Pacritinib, Once Daily", 
                    "Pacritinib, Twice Daily"
                ], 
                "intervention_name": "Pacritinib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Best Available Therapy", 
                "intervention_name": "Best Available Therapy", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Myelofibrosis", 
            "Post-Polycythemia Vera Myelofibrosis", 
            "Post-Essential Thrombocythemia Myelofibrosis", 
            "Primary Myelofibrosis", 
            "Polycythemia", 
            "Polycythemia Vera", 
            "Thrombocythemia, Essential", 
            "Thrombocythemia", 
            "Myeloproliferative Disorders", 
            "Bone Marrow Disease", 
            "Hematologic Diseases", 
            "Blood Platelet Disorders", 
            "Hemorrhagic Disorders", 
            "Splenomegaly", 
            "Pacritinib", 
            "MPN-SAF", 
            "MPN-SAF TSS", 
            "Anemia", 
            "Myeloproliferative", 
            "Myeloproliferative Neoplasm", 
            "Spleen", 
            "Spleen volume", 
            "Thrombocytopenia", 
            "SB1518"
        ], 
        "lastchanged_date": "June 4, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85715"
                    }, 
                    "name": "CTI Investigational Site 10027"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Urbana", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "61801"
                    }, 
                    "name": "CTI Investigational Site 10020"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Goshen", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46526"
                    }, 
                    "name": "CTI Investigational Site 10024"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46260"
                    }, 
                    "name": "CTI Investigational Site 10010"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Morristown", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07962"
                    }, 
                    "name": "CTI Investigational Site 10001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73104"
                    }, 
                    "name": "CTI Investigational Site 10011"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greenville", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29601"
                    }, 
                    "name": "CTI Investigational Site 10003"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Everett", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98201"
                    }, 
                    "name": "CTI Investigational Site 10018"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis", 
        "overall_contact": {
            "last_name": "Valentina Zhukova-Harrill, MD", 
            "phone": "+44 (0) 131-200-6320"
        }, 
        "overall_contact_backup": {
            "last_name": "Gordon Thomson, PM", 
            "phone": "+44 (0) 131-440-6441"
        }, 
        "overall_official": {
            "affiliation": "Cell Therapeutics", 
            "last_name": "Mary Campbell, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To compare the efficacy of two dose-schedule arms of pacritinib (pooled once-daily and twice-daily dosing arms) with that of Best Available Therapy in patients with thrombocytopenia and primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis; the efficacy measure for this analysis is the proportion of patients achieving a \u2265 35% reduction in spleen volume from baseline to week 24 by magnetic resonance imaging (MRI) or computed tomography (CT) and the proportion of patients achieving  a \u2265 50% reduction in total symptom score from baseline to Week 24 as measured by the Myeloproliferative Neoplasm Symptom Assessment Form 2.0.", 
            "measure": "Efficacy", 
            "safety_issue": "No", 
            "time_frame": "Baseline to Week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02055781"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To compare the efficacy of once-daily pacritinib with that of Best Available Therapy, as assessed by the proportion of patients achieving a \u2265 35% reduction in spleen volume from baseline to Week 24 by magnetic resonance imaging (MRI) or computed tomography (CT) and the proportion of patients achieving a  \u2265 50% reduction in the total symptom score from baseline to Week 24 on the Myeloproliferative Neoplasm Symptom Assessment Form 2.0.", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "Baseline  to Week 24"
            }, 
            {
                "description": "To compare the efficacy of twice-daily pacritinib with that of Best Available Therapy, as assessed by the proportion of patients achieving a  \u2265 35% reduction in spleen volume from baseline to Week 24 by magnetic resonance imaging (MRI) or computed tomography (CT) and the proportion of patients achieving a  \u2265 50% reduction in the total symptom score from baseline to Week 24 on the myeloproliferate Neoplasm Symptom Assessment Form 2.0.", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 24"
            }
        ], 
        "source": "Cell Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cell Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}